FDA Greasing the Wheel for Biosimilar Adoption Through Action PlanAllbiopro2018-07-26T01:36:33+09:007월 26th, 2018|
Why malaria parasites are faster than human immune cellsAllbiopro2018-07-26T01:35:16+09:007월 26th, 2018|
Gossamer Bio nets $230M in series B to advance portfolio against undisclosed targetsAllbiopro2018-07-25T02:10:46+09:007월 25th, 2018|
Think AbbVie can’t live without Humira? Check out today’s blockbuster Orilissa nodAllbiopro2018-07-25T02:10:19+09:007월 25th, 2018|
PhRMA lobby spend grows to $15.5M in the first half of 2018Allbiopro2018-07-25T02:09:53+09:007월 25th, 2018|
As Lilly’s pharma lineup delivers, cash-cow Elanco sets up for a much-anticipated IPOAllbiopro2018-07-25T02:09:27+09:007월 25th, 2018|
Biogen’s Spinraza zooms through blockbusterland, but analysts are fixated on Alzheimer’s dataAllbiopro2018-07-25T02:08:59+09:007월 25th, 2018|
Can Celgene’s latest Revlimid win reverse the company’s bad-news streak?Allbiopro2018-07-25T02:08:32+09:007월 25th, 2018|
GlaxoSmithKline launches full-on assault on Gilead with 2-drug HIV regimen dataAllbiopro2018-07-25T02:08:06+09:007월 25th, 2018|
Merck posts 96-week doravirine HIV data as PDUFA date nearsAllbiopro2018-07-25T02:07:39+09:007월 25th, 2018|
Biogen pays $27.5M upfront for 2 AliveGen muscle drugsAllbiopro2018-07-25T02:07:13+09:007월 25th, 2018|
Bristol-Myers Squibb, Tsinghua University pen drug discovery pactAllbiopro2018-07-25T02:06:47+09:007월 25th, 2018|
Neupogen Biosimilar Success: Pfizer Banks on Discounts and Patient ConfidenceAllbiopro2018-07-25T02:06:21+09:007월 25th, 2018|
Immune responses from Johnson & Johnson’s ‘mosaic’ HIV shot last 1 year: studyAllbiopro2018-07-25T02:05:54+09:007월 25th, 2018|
Biogen Revenue Grows 9% in 2Q, Plans to Push Ahead with Alzheimer’s and Acquired New AssetsAllbiopro2018-07-25T02:05:28+09:007월 25th, 2018|
